Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 1
2016 2
2017 2
2018 1
2019 4
2020 6
2021 6
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response.
Campopiano MC, Ghirri A, Prete A, Lorusso L, Puleo L, Cappagli V, Agate L, Bottici V, Brogioni S, Gambale C, Minaldi E, Matrone A, Elisei R, Molinaro E. Campopiano MC, et al. Among authors: cappagli v. Front Endocrinol (Lausanne). 2023 Apr 20;14:1133958. doi: 10.3389/fendo.2023.1133958. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37152950 Free PMC article. Review.
Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A, Lorusso L, Cappagli V, Pieruzzi L, Giani C, Sabini E, Passannati P, Puleo L, Matrone A, Pontillo-Contillo B, Battaglia V, Mazzeo S, Vitti P, Elisei R. Viola D, et al. Among authors: cappagli v. Endocr Relat Cancer. 2016 Apr;23(4):R185-205. doi: 10.1530/ERC-15-0555. Endocr Relat Cancer. 2016. PMID: 27207700 Review.
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.
Matrone A, Valerio L, Pieruzzi L, Giani C, Cappagli V, Lorusso L, Agate L, Puleo L, Viola D, Bottici V, Del Re M, Molinaro E, Danesi R, Elisei R. Matrone A, et al. Among authors: cappagli v. Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):319-334. doi: 10.1016/j.beem.2017.06.001. Epub 2017 Jun 15. Best Pract Res Clin Endocrinol Metab. 2017. PMID: 28911728 Review.
Calcitonin receptor expression in medullary thyroid carcinoma.
Cappagli V, Potes CS, Ferreira LB, Tavares C, Eloy C, Elisei R, Sobrinho-Simões M, Wookey PJ, Soares P. Cappagli V, et al. PeerJ. 2017 Sep 13;5:e3778. doi: 10.7717/peerj.3778. eCollection 2017. PeerJ. 2017. PMID: 28929017 Free PMC article.
Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib.
Prete A, Gambale C, Cappagli V, Bottici V, Rossi P, Caciagli M, Papini P, Taddei D, Ortori S, Gabbrielli L, Celi A, Materazzi G, Elisei R, Matrone A. Prete A, et al. Among authors: cappagli v. Eur J Endocrinol. 2022 Nov 29;187(6):905-915. doi: 10.1530/EJE-22-0643. Print 2022 Dec 1. Eur J Endocrinol. 2022. PMID: 36314655 Clinical Trial.
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center.
Prete A, Falcone M, Bottici V, Giani C, Tiseo G, Agate L, Matrone A, Cappagli V, Valerio L, Lorusso L, Minaldi E, Molinaro E, Elisei R. Prete A, et al. Among authors: cappagli v. Endocrine. 2021 May;72(2):332-339. doi: 10.1007/s12020-021-02650-z. Epub 2021 Feb 27. Endocrine. 2021. PMID: 33638758 Free PMC article.
28 results